Supportive Care in Cancer

, Volume 18, Issue 11, pp 1461–1468 | Cite as

Unanticipated toxicities from anticancer therapies: Survivors’ perspectives

  • Mona Gandhi
  • Karen Oishi
  • Beth Zubal
  • Mario E. LacoutureEmail author
Original Article



Improved therapies in oncology have resulted in increased survival across numerous malignancies, shifting attention to other aspects of the cancer experience. In particular, the impact of treatment-related toxicities has gained considerable attention, due to their physical and psychosocial effects, and possible impact on clinical outcome. These untoward events have not been examined from the survivors' perspective.


To identify and describe treatment-related toxicities having a negative effect on quality of life from the perspective of cancer survivors.


Quantitative study using written questionnaires and content analysis.


Cancer survivors' workshop across the United States.


A total of 379 participants from six survivor groups: breast (n = 250), ovarian (n = 27), lung (n = 23), colorectal (n = 15), genitourinary (n = 23), and other cancers (n = 45).

Outcome measures

Survivors' perceptions on treatment-related dermatologic, gastrointestinal, and constitutional toxicities.


Survivors reported an increased concern regarding dermatologic toxicities, including irritated and dry skin, after receiving their cancer treatment. These events had a negative effect on their lives. Although gastrointestinal and constitutional toxicities also had a negative effect, the concern over their development was unchanged prior to and after treatments.


The impact of dermatologic toxicities is unanticipated prior to cancer treatments. Since these events have a negative effect on survivors' lives, pretreatment counseling and effective interventions are vital in order to maximize quality of life and minimize unnecessary treatment interruptions or discontinuations.


Cancer Skin-related issues Hair loss Toxicities 



The authors would like to thank Marty McGough for statistical support, Carolyn Messner at CancerCare® for assistance with survey data, and Lindi skin® for sponsoring the survey. MEL is supported by a Zell Scholarship from the Robert H Lurie Comprehensive Cancer Center of Northwestern University and a Career Development Award from the Dermatology Foundation.


  1. 1.
    Jemal A, Thus MJ, Ries LA et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Ins 100(23):1672–1694CrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249 Epub 2009 May 27CrossRefPubMedGoogle Scholar
  3. 3.
    MMWR Morb Mortal Wkly Rep. (2004) 53(24):526–529Google Scholar
  4. 4.
    Jemal A, Center MM, Ward E et al (2009) Cancer occurrence. Methods Mol Biol 471:3–29CrossRefPubMedGoogle Scholar
  5. 5.
    Boone SL, Rademaker A, Liu D et al (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72:152–159CrossRefPubMedGoogle Scholar
  6. 6.
    Wildiers H (2007) Mastering chemotherapy dose reduction in elderly cancer patients. Eur J Cancer 43(15):2235–2241CrossRefPubMedGoogle Scholar
  7. 7.
    Frith H, Harcourt D, Fussell A (2007) Anticipating an altered appearance: women undergoing chemotherapy treatment for breast cancer. Eur J Oncol Nurs 11(5):385–391CrossRefPubMedGoogle Scholar
  8. 8.
    Aspinwall LG, Taylor SE (1997) A stitch in time: self-regulation and proactive coping. Psychol Bull 121(3):417–436CrossRefPubMedGoogle Scholar
  9. 9.
    Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70CrossRefPubMedGoogle Scholar
  10. 10.
    Bentzen SM, Trotti A (2007) Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25(26):4096–4103CrossRefPubMedGoogle Scholar
  11. 11.
    Loprinzi CL, Barton DL, Jatoi A et al (2007) Symptom control trials: a 20-year experience. J Support Oncol 5(3):119–125PubMedGoogle Scholar
  12. 12.
    McCaughan E, Thompson K (2000) Informational needs of cancer patients receiving chemotherapy at a day-case unit in Northern Ireland. J Adv Nurs 6:851–858Google Scholar
  13. 13.
    Montgomery N, Tomoyasu D, Bovbjerg M et al (1998) Patient's pre-treatment expectations of chemotherapy-related nausea are an independent predictor of anticipatory nausea. The Society of Behavioural Medicine 20((2):104–108CrossRefGoogle Scholar
  14. 14.
    Burish TG, Snyder SL, Jenkins RA (1991) Preparing patients for cancer chemotherapy: effect of coping preparation and relaxation interventions. J Consult Clin Psychol 59(4):518–525CrossRefPubMedGoogle Scholar
  15. 15.
    Lindley C, McCune JS, Thomason TE et al (1999) Perception of chemotherapy side effects: cancer versus noncancer patients. Cancer Pract 7(2):59–65CrossRefPubMedGoogle Scholar
  16. 16.
    Hackbarth M, Haas N, Fotopolou C et al (2008) Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancer. Results of a prospective study. Support Care Cancer 16:267–273CrossRefPubMedGoogle Scholar
  17. 17.
    Fallowfield LJ (2008) Treatment decision-making in breast cancer: the patient–doctor relationship. Breast Cancer Res Treat 112:5–13CrossRefPubMedGoogle Scholar
  18. 18.
    Simminoff LA (1992) Improving communication with cancer patients. Oncology 6:83–87Google Scholar
  19. 19.
    Butler L, Bacon M, Carey M et al (2004) Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Ocol 22:2461–2468CrossRefGoogle Scholar
  20. 20.
    McInnes DK, Cleary PD, Stein KD et al (2008) Perceptions of cancer-related information among cancer survivors: a report from the American Cancer Society's studies of cancer survivors. Cancer 113(6):1471–1479CrossRefPubMedGoogle Scholar
  21. 21.
    Richardson LC, Wang W, Hartzema AG et al (2007) The role of health related quality of life in early discontinuation of chemotherapy for breast cancer. Breast J 13(6):581–587CrossRefPubMedGoogle Scholar
  22. 22.
    Hall G, Phillips TJ (2005) Estrogen and skin: the effects of estrogen, menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol 53(4):555–568CrossRefPubMedGoogle Scholar
  23. 23.
    Fromme EK, Eilers KM, Mori M et al (2004) How accurate is clinician reporting of chemotherapy adverse events? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol 22(17):3485–3490CrossRefPubMedGoogle Scholar
  24. 24.
    Viele CS (2007) Managing oral chemotherapy: the healthcare practitioner's role. Am J Health Syst Pharm 64(9 Suppl 5):S25–S32CrossRefPubMedGoogle Scholar
  25. 25.
    Dodd MJ (1982) Assessing patient self-care for the side effects of cancer chemotherapy—part 1. Cancer Nurs 5(6):447–451CrossRefPubMedGoogle Scholar
  26. 26.
    Carelle N, Plotto E, Bellanger A et al (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95(1):155–163CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Mona Gandhi
    • 1
  • Karen Oishi
    • 2
  • Beth Zubal
    • 3
  • Mario E. Lacouture
    • 1
    • 4
    Email author
  1. 1.Department of DermatologyNorthwestern University’s Feinberg School of MedicineChicagoUSA
  2. 2.University of Texas M.D. Anderson Cancer CenterHoustonUSA
  3. 3.Washington University School of MedicineSt. LouisUSA
  4. 4.SERIES Clinic, Robert H Lurie Comprehensive Cancer CenterNorthwestern University’s Feinberg School of MedicineChicagoUSA

Personalised recommendations